Regeneron Pharmaceuticals REGN Collaboration revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's collaboration revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's collaboration revenue — revenue?
- Regeneron Pharmaceuticals (REGN) reported collaboration revenue — revenue of $1.9B in Q1 2026.
- How has Regeneron Pharmaceuticals's collaboration revenue — revenue changed year-over-year?
- Regeneron Pharmaceuticals's collaboration revenue — revenue increased by 24.1% year-over-year, from $1.53B to $1.9B.
- What is the long-term trend for Regeneron Pharmaceuticals's collaboration revenue — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's collaboration revenue — revenue has grown at a 18.9% compound annual growth rate (CAGR), from $3.67B to $7.33B.
- What does collaboration revenue — revenue mean?
- Collaboration revenue represents income generated through strategic partnerships and joint development agreements with other pharmaceutical or biotechnology entities. This revenue stream typically includes profit-sharing arrangements, milestone payments, and reimbursement for shared research and development costs associated with co-developed therapeutic assets. It reflects the company's ability to leverage external expertise and capital to accelerate drug discovery and commercialization efforts.